Endocrinol Metab.  2017 Mar;32(1):62-67. 10.3803/EnM.2017.32.1.62.

Articles in Endocrinology and Metabolism in 2016

  • 1Department of Endocrinology and Metabolism, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea. drlwy@hanmail.net


No abstract available.

MeSH Terms



1. Lo TE, Uy AT, Maningat PD. Well-differentiated thyroid cancer: the Philippine General Hospital experience. Endocrinol Metab (Seoul). 2016; 31:72–79.
2. Jeon MJ, Kim WG, Sim S, Lim S, Kwon H, Kim TY, et al. Low prevalence of somatic TERT promoter mutations in classic papillary thyroid carcinoma. Endocrinol Metab (Seoul). 2016; 31:100–104.
3. Jauculan MC, Buenaluz-Sedurante M, Jimeno CA. Risk factors associated with disease recurrence among patients with low-risk papillary thyroid cancer treated at the University of the Philippines-Philippine General Hospital. Endocrinol Metab (Seoul). 2016; 31:113–119.
4. Park S, Kim TY, Sim S, Lim S, Kim M, Kwon H, et al. Thyrotoxic periodic paralysis and polymorphisms of the ADRB2, AR, and GABRA3 genes in men with Graves disease. Endocrinol Metab (Seoul). 2016; 31:142–146.
5. Canto AU, Dominguez PN, Jimeno CA, Obaldo JM, Ogbac RV. Comparison of fixed versus calculated activity of radioiodine for the treatment of graves disease in adults. Endocrinol Metab (Seoul). 2016; 31:168–173.
6. Moon JH. Endocrine risk factors for cognitive impairment. Endocrinol Metab (Seoul). 2016; 31:185–192.
7. Wiersinga WM. Clinical relevance of environmental factors in the pathogenesis of autoimmune thyroid disease. Endocrinol Metab (Seoul). 2016; 31:213–222.
8. Kwon H, Kim WG, Jang EK, Kim M, Park S, Jeon MJ, et al. Usefulness of measuring thyroid stimulating antibody at the time of antithyroid drug withdrawal for predicting relapse of Graves disease. Endocrinol Metab (Seoul). 2016; 31:300–310.
9. Kim HJ, Bae JC, Park HK, Byun DW, Suh K, Yoo MH, et al. Triiodothyronine levels are independently associated with metabolic syndrome in euthyroid middle-aged subjects. Endocrinol Metab (Seoul). 2016; 31:311–319.
10. Yi KH. The revised 2016 Korean Thyroid Association guidelines for thyroid nodules and cancers: differences from the 2015 American Thyroid Association guidelines. Endocrinol Metab (Seoul). 2016; 31:373–378.
11. Yoo WS, Chung HK. Recent advances in autoimmune thyroid diseases. Endocrinol Metab (Seoul). 2016; 31:379–385.
12. Yim CH. Update on the management of thyroid disease during pregnancy. Endocrinol Metab (Seoul). 2016; 31:386–391.
13. Kim BH, Kim IJ. Recent updates on the management of medullary thyroid carcinoma. Endocrinol Metab (Seoul). 2016; 31:392–399.
14. Topliss DJ. Clinical update in aspects of the management of autoimmune thyroid diseases. Endocrinol Metab (Seoul). 2016; 31:493–499.
15. Kwon H, Kim WG, Eszlinger M, Paschke R, Song DE, Kim M, et al. Molecular diagnosis using residual liquid-based cytology materials for patients with nondiagnostic or indeterminate thyroid nodules. Endocrinol Metab (Seoul). 2016; 31:586–591.
16. Choi KM. The impact of organokines on insulin resistance, inflammation, and atherosclerosis. Endocrinol Metab (Seoul). 2016; 31:1–6.
17. Lee YH, Bang H, Kim DJ. How to establish clinical prediction models. Endocrinol Metab (Seoul). 2016; 31:38–44.
18. Oh TJ. In vivo models for incretin research: from the intestine to the whole body. Endocrinol Metab (Seoul). 2016; 31:45–51.
19. Hong JY, Park KY, Kim BJ, Hwang WM, Kim DH, Lim DM. Effects of short-term exenatide treatment on regional fat distribution, glycated hemoglobin levels, and aortic pulse wave velocity of obese type 2 diabetes mellitus patients. Endocrinol Metab (Seoul). 2016; 31:80–85.
20. Lee JI, Kim MC, Moon BS, Song YS, Han EN, Lee HS, et al. The relationship between 10-year cardiovascular risk calculated using the pooled cohort equation and the severity of non-alcoholic fatty liver disease. Endocrinol Metab (Seoul). 2016; 31:86–92.
21. Tokatli A, Kilicaslan F, Alis M, Yiginer O, Uzun M. Prolonged Tp-e interval, Tp-e/QT ratio and Tp-e/QTc ratio in patients with type 2 diabetes mellitus. Endocrinol Metab (Seoul). 2016; 31:105–112.
22. Lee HS, Jung CH, Kim SR, Jang HC, Park CY. PROPIT Study Team. Effect of pitavastatin treatment on ApoB-48 and Lp-PLA(2) in patients with metabolic syndrome: substudy of PROspective comparative clinical study evaluating the efficacy and safety of PITavastatin in patients with metabolic syndrome. Endocrinol Metab (Seoul). 2016; 31:120–126.
23. Son YJ, Kim J, Park HJ, Park SE, Park CY, Lee WY, et al. Association of waist-height ratio with diabetes risk: a 4-year longitudinal retrospective study. Endocrinol Metab (Seoul). 2016; 31:127–133.
24. Suh S, Kim MY, Kim SK, Hur KY, Park MK, Kim DK, et al. Glucose-dependent insulinotropic peptide level is associated with the development of type 2 diabetes mellitus. Endocrinol Metab (Seoul). 2016; 31:134–141.
25. Bae J, Lee MJ, Choe EY, Jung CH, Wang HJ, Kim MS, et al. Effects of dipeptidyl peptidase-4 inhibitors on hyperglycemia and blood cyclosporine levels in renal transplant patients with diabetes: a pilot study. Endocrinol Metab (Seoul). 2016; 31:161–167.
26. Won JC, Park TS. Recent advances in diagnostic strategies for diabetic peripheral neuropathy. Endocrinol Metab (Seoul). 2016; 31:230–238.
27. Bae JC. Diabetes drugs and cardiovascular safety. Endocrinol Metab (Seoul). 2016; 31:239–244.
28. Kim SS, Kim JH, Kim IJ. Current challenges in diabetic nephropathy: early diagnosis and ways to improve outcomes. Endocrinol Metab (Seoul). 2016; 31:245–253.
29. Lee JH, Song SJ. Current challenges in diabetic retinopathy: are we really doing better? Endocrinol Metab (Seoul). 2016; 31:254–257.
30. Kang YM, Jung CH. Cardiovascular effects of glucagonlike peptide-1 receptor agonists. Endocrinol Metab (Seoul). 2016; 31:258–274.
31. Kim MK, Jung HS, Kwak SH, Cho YM, Park KS, Kim SY. 1,5-Anhydro-D-glucitol could reflect hypoglycemia risk in patients with type 2 diabetes receiving insulin therapy. Endocrinol Metab (Seoul). 2016; 31:284–291.
32. Song SO, Lee YH, Kim DW, Song YD, Nam JY, Park KH, et al. Trends in diabetes incidence in the last decade based on Korean National Health Insurance Claims Data. Endocrinol Metab (Seoul). 2016; 31:292–299.
33. Kim JD, Kang SJ, Lee MK, Park SE, Rhee EJ, Park CY, et al. C-peptide-based index is more related to incident type 2 diabetes in non-diabetic subjects than insulin-based index. Endocrinol Metab (Seoul). 2016; 31:320–327.
34. Noh J. The diabetes epidemic in Korea. Endocrinol Metab (Seoul). 2016; 31:349–353.
35. Kim JD, Lee WY. Insulin secretory capacity and insulin resistance in Korean type 2 diabetes mellitus patients. Endocrinol Metab (Seoul). 2016; 31:354–360.
36. Lee SA, Koh G, Cho SJ, Yoo SY, Chin SO. Correlation of glypican-4 level with basal active glucagon-like peptide 1 level in patients with type 2 diabetes mellitus. Endocrinol Metab (Seoul). 2016; 31:439–445.
37. Ha KH, Kim DJ. Epidemiology of childhood obesity in Korea. Endocrinol Metab (Seoul). 2016; 31:510–518.
38. Roh E, Kim MS. Brain regulation of energy metabolism. Endocrinol Metab (Seoul). 2016; 31:519–524.
39. Choi YB. Current status of bariatric and metabolic surgery in Korea. Endocrinol Metab (Seoul). 2016; 31:525–532.
40. Ahn HJ, Moon DS, Kang DY, Lee JI, Kim DY, Kim JH, et al. Urinary albumin excretion reflects cardiovascular risk in postmenopausal women without diabetes: the 2011 to 2013 Korean National Health and Nutrition Examination Survey. Endocrinol Metab (Seoul). 2016; 31:537–546.
41. Park J, Lee ES, Lee DY, Kim J, Park SE, Park CY, et al. Waist circumference as a marker of obesity is more predictive of coronary artery calcification than body mass index in apparently healthy Korean adults: the Kangbuk Samsung Health Study. Endocrinol Metab (Seoul). 2016; 31:559–566.
42. Lee HW, Jo AR, Yi DW, Kang YH, Son SM. Prevalent rate of nonalbuminuric renal insufficiency and its association with cardiovascular disease event in Korean type 2 diabetes. Endocrinol Metab (Seoul). 2016; 31:577–585.
43. Choi YJ. Dual-energy X-ray absorptiometry: beyond bone mineral density determination. Endocrinol Metab (Seoul). 2016; 31:25–30.
44. Choi HS, Kim KJ, Rhee Y, Lim SK. Serum gamma-glutamyl transferase is inversely associated with bone mineral density independently of alcohol consumption. Endocrinol Metab (Seoul). 2016; 31:64–71.
45. Kim SW, Cho EH. High levels of serum DPP-4 activity are associated with low bone mineral density in obese postmenopausal women. Endocrinol Metab (Seoul). 2016; 31:93–99.
46. Mendoza ES, Lopez AA, Valdez VA, Mercado-Asis LB. Osteoporosis and prevalent fractures among adult Filipino men screened for bone mineral density in a tertiary hospital. Endocrinol Metab (Seoul). 2016; 31:433–438.
47. Kim H, Ahn SH, Shin C, Lee SH, Kim BJ, Koh JM. The association of higher plasma macrophage migration inhibitory factor levels with lower bone mineral density and higher bone turnover rate in postmenopausal women. Endocrinol Metab (Seoul). 2016; 31:454–461.
48. Jeong HM, Cho SW, Park SI. Osteoblasts are the centerpiece of the metastatic bone microenvironment. Endocrinol Metab (Seoul). 2016; 31:485–492.
49. Salamat MR, Salamat AH, Janghorbani M. Association between obesity and bone mineral density by gender and menopausal status. Endocrinol Metab (Seoul). 2016; 31:547–558.
50. Lee JH, Kim EK, Hong AR, Roh E, Bae JH, Kim JH, et al. Radiographic characteristics of adrenal masses in oncologic patients. Endocrinol Metab (Seoul). 2016; 31:147–152.
51. Baek JH, Kim SK, Jung JH, Hahm JR, Jung J. Recovery of adrenal function in patients with glucocorticoids induced secondary adrenal insufficiency. Endocrinol Metab (Seoul). 2016; 31:153–160.
52. Kim JH, Park KS, Hong AR, Shin CS, Kim SY, Kim SW. Diagnostic role of captopril challenge test in Korean subjects with high aldosterone-to-renin ratios. Endocrinol Metab (Seoul). 2016; 31:277–283.
53. Kim HK, Yoon JH, Jeong YA, Kang HC. The recovery of hypothalamic-pituitary-adrenal axis is rapid in subclinical Cushing syndrome. Endocrinol Metab (Seoul). 2016; 31:592–597.
54. Han SJ, Kim KS, Kim W, Kim JH, Lee YH, Nam JS, et al. Obesity and hyperglycemia in Korean men with Klinefelter syndrome: the Korean Endocrine Society Registry. Endocrinol Metab (Seoul). 2016; 31:598–603.
55. Kim SJ, Kim SH, Kim JH, Hwang S, Yoo HJ. Understanding metabolomics in biomedical research. Endocrinol Metab (Seoul). 2016; 31:7–16.
56. Yuk JM, Jin HS, Jo EK. Small heterodimer partner and innate immune regulation. Endocrinol Metab (Seoul). 2016; 31:17–24.
57. Leem J, Lee IK. Mechanisms of vascular calcification: the pivotal role of pyruvate dehydrogenase kinase 4. Endocrinol Metab (Seoul). 2016; 31:52–61.
58. Liu X, Herbison AE. Kisspeptin regulation of neuronal activity throughout the central nervous system. Endocrinol Metab (Seoul). 2016; 31:193–205.
59. Kang Y. Dissecting tumor-stromal interactions in breast cancer bone metastasis. Endocrinol Metab (Seoul). 2016; 31:206–212.
60. Ku CR, Cho YH, Hong ZY, Lee H, Lee SJ, Hong SS, et al. The effects of high fat diet and resveratrol on mitochondrial activity of brown adipocytes. Endocrinol Metab (Seoul). 2016; 31:328–335.
61. Gavrieli A, Mantzoros CS. Novel molecules regulating energy homeostasis: physiology and regulation by macronutrient intake and weight loss. Endocrinol Metab (Seoul). 2016; 31:361–372.
Full Text Links
  • ENM
export Copy
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr